Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XFOR |
---|---|---|
09:32 ET | 28198 | 1.415 |
09:34 ET | 13543 | 1.42 |
09:36 ET | 25515 | 1.405 |
09:38 ET | 14876 | 1.4 |
09:39 ET | 30738 | 1.4 |
09:41 ET | 1500 | 1.41 |
09:43 ET | 29195 | 1.42 |
09:45 ET | 17465 | 1.4159 |
09:48 ET | 5700 | 1.4168 |
09:50 ET | 4595 | 1.405 |
09:52 ET | 1571 | 1.4 |
09:54 ET | 5873 | 1.4044 |
09:56 ET | 68401 | 1.41 |
09:57 ET | 32750 | 1.4 |
09:59 ET | 3773 | 1.4 |
10:01 ET | 24345 | 1.42 |
10:03 ET | 12866 | 1.405 |
10:06 ET | 4242 | 1.4 |
10:08 ET | 8885 | 1.405 |
10:10 ET | 1355 | 1.405 |
10:12 ET | 110550 | 1.37 |
10:14 ET | 61675 | 1.36 |
10:15 ET | 48048 | 1.365 |
10:17 ET | 45805 | 1.35 |
10:19 ET | 7074 | 1.36 |
10:21 ET | 161233 | 1.35 |
10:24 ET | 49976 | 1.35 |
10:26 ET | 7339 | 1.3499 |
10:28 ET | 26531 | 1.3594 |
10:30 ET | 7500 | 1.36 |
10:32 ET | 7629 | 1.35 |
10:33 ET | 3708 | 1.355 |
10:35 ET | 27926 | 1.36 |
10:37 ET | 7500 | 1.365 |
10:39 ET | 6631 | 1.368 |
10:42 ET | 10685 | 1.365 |
10:44 ET | 15873 | 1.37 |
10:46 ET | 7970 | 1.365 |
10:48 ET | 2840 | 1.365 |
10:50 ET | 8157 | 1.36 |
10:51 ET | 9696 | 1.365 |
10:53 ET | 3483 | 1.3601 |
10:55 ET | 3200 | 1.36 |
10:57 ET | 1863 | 1.36 |
11:00 ET | 23300 | 1.35 |
11:02 ET | 13166 | 1.35 |
11:04 ET | 7232 | 1.35 |
11:06 ET | 2800 | 1.355 |
11:08 ET | 27951 | 1.335 |
11:09 ET | 35655 | 1.335 |
11:11 ET | 8717 | 1.345 |
11:13 ET | 7402 | 1.34 |
11:15 ET | 9070 | 1.3499 |
11:18 ET | 11510 | 1.35 |
11:20 ET | 1100 | 1.349 |
11:22 ET | 11738 | 1.34 |
11:24 ET | 7856 | 1.345 |
11:26 ET | 44657 | 1.335 |
11:27 ET | 15724 | 1.3301 |
11:29 ET | 53317 | 1.35 |
11:31 ET | 11687 | 1.35 |
11:33 ET | 7900 | 1.341 |
11:36 ET | 3820 | 1.345 |
11:38 ET | 684 | 1.34 |
11:40 ET | 4532 | 1.34 |
11:42 ET | 1641 | 1.35 |
11:44 ET | 389 | 1.34 |
11:45 ET | 16109 | 1.3501 |
11:47 ET | 16383 | 1.349 |
11:49 ET | 1900 | 1.35 |
11:51 ET | 4302 | 1.345 |
11:54 ET | 2358 | 1.3409 |
11:56 ET | 1002 | 1.345 |
11:58 ET | 14781 | 1.34 |
12:00 ET | 2620 | 1.345 |
12:02 ET | 3463 | 1.335 |
12:03 ET | 14225 | 1.33 |
12:05 ET | 6856 | 1.34 |
12:07 ET | 6137 | 1.335 |
12:09 ET | 400 | 1.33 |
12:12 ET | 156953 | 1.33 |
12:14 ET | 86664 | 1.325 |
12:16 ET | 4051 | 1.327 |
12:18 ET | 15795 | 1.3289 |
12:20 ET | 50600 | 1.3299 |
12:21 ET | 56151 | 1.33 |
12:23 ET | 755 | 1.3299 |
12:25 ET | 70048 | 1.315 |
12:27 ET | 13432 | 1.31 |
12:30 ET | 24461 | 1.305 |
12:32 ET | 51696 | 1.31 |
12:34 ET | 24708 | 1.305 |
12:36 ET | 22840 | 1.315 |
12:38 ET | 26025 | 1.32 |
12:39 ET | 3695 | 1.31 |
12:41 ET | 2721 | 1.3199 |
12:43 ET | 10958 | 1.315 |
12:45 ET | 1400 | 1.31 |
12:48 ET | 2262 | 1.315 |
12:50 ET | 2466 | 1.31 |
12:52 ET | 505 | 1.3188 |
12:54 ET | 12716 | 1.315 |
12:56 ET | 9686 | 1.3199 |
12:57 ET | 20670 | 1.315 |
12:59 ET | 3500 | 1.315 |
01:01 ET | 3499 | 1.315 |
01:03 ET | 6241 | 1.31 |
01:06 ET | 2329 | 1.31 |
01:08 ET | 1301 | 1.315 |
01:10 ET | 2652 | 1.31 |
01:12 ET | 20623 | 1.325 |
01:14 ET | 13249 | 1.325 |
01:15 ET | 19000 | 1.33 |
01:17 ET | 2095 | 1.32 |
01:19 ET | 18199 | 1.33 |
01:21 ET | 18088 | 1.325 |
01:24 ET | 96583 | 1.32 |
01:26 ET | 16815 | 1.315 |
01:28 ET | 2505 | 1.3125 |
01:30 ET | 3038 | 1.31 |
01:32 ET | 658 | 1.315 |
01:33 ET | 12283 | 1.32 |
01:35 ET | 5753 | 1.33 |
01:37 ET | 2714 | 1.33 |
01:39 ET | 1063 | 1.325 |
01:42 ET | 710 | 1.33 |
01:44 ET | 9521 | 1.325 |
01:46 ET | 4390 | 1.33 |
01:48 ET | 4647 | 1.33 |
01:51 ET | 1975 | 1.335 |
01:53 ET | 492 | 1.33 |
01:55 ET | 600 | 1.335 |
01:57 ET | 8176 | 1.33 |
02:00 ET | 2453 | 1.34 |
02:02 ET | 719 | 1.34 |
02:04 ET | 3857 | 1.33 |
02:06 ET | 2600 | 1.33 |
02:08 ET | 2400 | 1.34 |
02:09 ET | 400 | 1.33 |
02:11 ET | 44006 | 1.32 |
02:13 ET | 4658 | 1.325 |
02:15 ET | 501 | 1.32 |
02:18 ET | 15165 | 1.325 |
02:20 ET | 7132 | 1.3203 |
02:22 ET | 12975 | 1.33 |
02:24 ET | 4877 | 1.32 |
02:26 ET | 500 | 1.33 |
02:27 ET | 1447 | 1.32 |
02:29 ET | 3323 | 1.325 |
02:31 ET | 749 | 1.325 |
02:33 ET | 16904 | 1.32 |
02:36 ET | 200 | 1.32 |
02:38 ET | 1238 | 1.325 |
02:40 ET | 1500 | 1.325 |
02:42 ET | 2815 | 1.32 |
02:44 ET | 3152 | 1.32 |
02:45 ET | 1444 | 1.32 |
02:47 ET | 7288 | 1.325 |
02:49 ET | 2138 | 1.32 |
02:51 ET | 2490 | 1.32 |
02:54 ET | 650 | 1.32 |
02:56 ET | 10776 | 1.32 |
02:58 ET | 2760 | 1.32 |
03:00 ET | 2000 | 1.32 |
03:02 ET | 4286 | 1.325 |
03:03 ET | 2200 | 1.33 |
03:05 ET | 3826 | 1.33 |
03:07 ET | 3932 | 1.33 |
03:09 ET | 800 | 1.33 |
03:12 ET | 1846 | 1.33 |
03:14 ET | 3001 | 1.32 |
03:16 ET | 3051 | 1.33 |
03:18 ET | 1469 | 1.32 |
03:20 ET | 6101 | 1.325 |
03:21 ET | 3445 | 1.33 |
03:23 ET | 1252 | 1.33 |
03:25 ET | 2200 | 1.32 |
03:27 ET | 2683 | 1.32 |
03:30 ET | 20628 | 1.32 |
03:32 ET | 76178 | 1.31 |
03:34 ET | 34534 | 1.315 |
03:36 ET | 43567 | 1.305 |
03:38 ET | 20679 | 1.31 |
03:39 ET | 86636 | 1.3301 |
03:41 ET | 72809 | 1.35 |
03:43 ET | 66911 | 1.33 |
03:45 ET | 67860 | 1.35 |
03:48 ET | 13769 | 1.341 |
03:50 ET | 2222 | 1.34 |
03:52 ET | 74511 | 1.34 |
03:54 ET | 16260 | 1.34 |
03:56 ET | 204024 | 1.365 |
03:57 ET | 150567 | 1.38 |
03:59 ET | 593478 | 1.39 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
X4 Pharmaceuticals Inc | 233.4M | -2.3x | --- |
Trevi Therapeutics Inc | 237.9M | -11.8x | --- |
Design Therapeutics Inc | 227.7M | -3.4x | --- |
Atossa Therapeutics Inc | 225.5M | -7.6x | --- |
Cardiff Oncology Inc | 238.6M | -5.8x | --- |
Acumen Pharmaceuticals Inc | 243.3M | -3.7x | --- |
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $233.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 167.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-0.60 |
Book Value | $0.31 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.